Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ARDMQNASDAQ:BBLGNASDAQ:LGMKNASDAQ:NDRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDMQAradigm$0.05$0.05$0.02▼$0.20$764KN/A21,923 shsN/ABBLGBone Biologics$4.74-10.3%$4.51$3.42▼$25.50$2.58M0.75236,762 shs36,919 shsLGMKLogicMark$0.00$0.01$0.00▼$24.00$2.31M1.6749.51 million shs10.89 million shsNDRAENDRA Life Sciences$3.45-5.7%$3.93$2.90▼$286.48$2.55M-0.21141,922 shs55,616 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDMQAradigm0.00%0.00%0.00%0.00%0.00%BBLGBone Biologics0.00%-1.51%+9.38%-5.19%-47.74%LGMKLogicMark0.00%-4.76%-69.23%-97.82%-99.98%NDRAENDRA Life Sciences0.00%+2.68%+6.81%-16.06%-99.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDMQAradigmN/AN/AN/AN/AN/AN/AN/AN/ABBLGBone Biologics1.4176 of 5 stars0.05.00.00.02.60.01.3LGMKLogicMark0.4832 of 5 stars0.03.00.00.02.50.00.6NDRAENDRA Life Sciences2.7143 of 5 stars3.54.00.00.02.20.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDMQAradigm 0.00N/AN/AN/ABBLGBone Biologics 0.00N/AN/AN/ALGMKLogicMark 0.00N/AN/AN/ANDRAENDRA Life Sciences 3.00Buy$50.001,349.28% UpsideCurrent Analyst Ratings BreakdownLatest ARDMQ, BBLG, NDRA, and LGMK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025NDRAENDRA Life SciencesAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $50.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDMQAradigmN/AN/AN/AN/AN/AN/ABBLGBone BiologicsN/AN/AN/AN/A$7.42 per shareN/ALGMKLogicMark$9.88M0.23N/AN/A$148.65 per share0.00NDRAENDRA Life SciencesN/AN/AN/AN/A$1,170.18 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDMQAradigmN/AN/A0.00∞N/AN/AN/AN/AN/ABBLGBone Biologics-$8.95MN/A0.00N/AN/AN/A-124.71%-111.64%8/8/2025 (Estimated)LGMKLogicMark-$14.55M-$223.50N/A∞N/A-141.96%-124.91%-92.05%8/12/2025 (Estimated)NDRAENDRA Life Sciences-$10.06M-$172.04N/AN/AN/AN/A-127.39%-103.77%8/20/2025 (Estimated)Latest ARDMQ, BBLG, NDRA, and LGMK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025LGMKLogicMark-$0.03-$0.12-$0.09-$0.12$2.23 million$2.59 million5/12/2025Q1 2025BBLGBone Biologics-$2.88-$1.92+$0.96-$0.32N/AN/A3/31/2025Q4 2024NDRAENDRA Life Sciences-$4.10-$9.40-$5.30-$20.78N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDMQAradigmN/AN/AN/AN/AN/ABBLGBone BiologicsN/AN/AN/AN/AN/ALGMKLogicMarkN/AN/AN/AN/AN/ANDRAENDRA Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDMQAradigmN/AN/AN/ABBLGBone BiologicsN/A14.8914.89LGMKLogicMarkN/A3.733.29NDRAENDRA Life SciencesN/A6.106.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDMQAradigmN/ABBLGBone Biologics34.30%LGMKLogicMark7.88%NDRAENDRA Life Sciences1.19%Insider OwnershipCompanyInsider OwnershipARDMQAradigm4.50%BBLGBone Biologics6.10%LGMKLogicMark1.33%NDRAENDRA Life Sciences0.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDMQAradigm2315.28 millionN/ANot OptionableBBLGBone Biologics2545,0002.31 millionNot OptionableLGMKLogicMark20576.31 million2.65 millionNo DataNDRAENDRA Life Sciences20738,000537,000Not OptionableARDMQ, BBLG, NDRA, and LGMK HeadlinesRecent News About These CompaniesENDRA Life Sciences (NASDAQ:NDRA) Upgraded to "Hold" at Wall Street ZenJune 9, 2025 | americanbankingnews.comENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial ResultsMay 15, 2025 | businesswire.comENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business UpdateMarch 31, 2025 | finance.yahoo.comENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 TherapiesMarch 31, 2025 | businesswire.comENDRA Life Sciences Inc Registered Shs NDRAFebruary 2, 2025 | morningstar.comWhat Makes ENDRA Life Sciences (NDRA) a New Strong Buy StockJanuary 28, 2025 | zacks.comENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price RequirementNovember 22, 2024 | businesswire.comENDRA Life Sciences Reports Q3 2024 Results and ProgressNovember 16, 2024 | markets.businessinsider.comENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business UpdateNovember 15, 2024 | finance.yahoo.comStudy Highlighting ENDRA Life Sciences’ TAEUS Technology in Patients with High BMI to be Presented at AASLD’s The Liver Meeting® 2024November 12, 2024 | finance.yahoo.comENDRA Life Sciences Inc trading halted, news pendingNovember 7, 2024 | markets.businessinsider.comENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European PatentNovember 6, 2024 | finance.yahoo.comWave Life Sciences: Pioneering RNA-Editing with Promising Obesity and Cardiovascular InnovationsNovember 4, 2024 | markets.businessinsider.comWave Life Sciences: Pioneering RNA Editing Technology with Promising Therapeutic PipelineOctober 31, 2024 | markets.businessinsider.comWhat’s Driving ENDRA Life Sciences Inc (NDRA) Stock’s 36.45% Surge Over the Past Month?October 28, 2024 | bovnews.comEndra activates TAEUS system to initiate clinical study at LMU in GermanyOctober 23, 2024 | markets.businessinsider.comLife sciences investor Dimension seeks to raise $500M second fundOctober 23, 2024 | endpts.comWhy ENDRA Life Sciences (NDRA) Stock Is Up 140%October 23, 2024 | benzinga.comLife Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual functionOctober 22, 2024 | ophthalmologytimes.comENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in GermanyOctober 22, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARDMQ, BBLG, NDRA, and LGMK Company DescriptionsAradigm OTCMKTS:ARDMQ$0.05 0.00 (0.00%) As of 06/30/2020Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung.Bone Biologics NASDAQ:BBLG$4.74 -0.55 (-10.32%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$5.06 +0.32 (+6.76%) As of 06/13/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.LogicMark NASDAQ:LGMK$0.0040 0.00 (0.00%) As of 06/13/2025 03:56 PM EasternLogicMark, Inc. provides personal emergency response systems (PERS), health communications devices, and Internet of Things (IoT) technology that creates a connected care platform in the United States. The company's devices provide people with the ability to receive care at home and age independently and to check, manage, and monitor a loved one's health and safety remotely. It also manufactures and distributes non-monitored and monitored personal emergency response systems, which are offered through the United States Veterans Health Administration (VHA), direct-to-consumers, healthcare durable medical equipment dealers and distributors, monitored security dealers and distributors, and its ecommerce website logicmark.com and Amazon.com. The company was formerly known as Nxt-ID, Inc. and changed its name to LogicMark, Inc. in March 2022. LogicMark, Inc. was founded in 2006 and is based in Louisville, Kentucky.ENDRA Life Sciences NASDAQ:NDRA$3.45 -0.21 (-5.74%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.52 +0.07 (+2.14%) As of 06/13/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
